GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lattice Biologics Ltd (OTCPK:LBLTF) » Definitions » 12-1 Month Momentum %

Lattice Biologics (Lattice Biologics) 12-1 Month Momentum % : N/A% (As of Apr. 29, 2024)


View and export this data going back to 2001. Start your Free Trial

What is Lattice Biologics 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-04-29), Lattice Biologics's 12-1 Month Momentum % is N/A%.

The industry rank for Lattice Biologics's 12-1 Month Momentum % or its related term are showing as below:

LBLTF's 12-1 Month Momentum % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: -17.415
* Ranked among companies with meaningful 12-1 Month Momentum % only.

Competitive Comparison of Lattice Biologics's 12-1 Month Momentum %

For the Medical Devices subindustry, Lattice Biologics's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lattice Biologics's 12-1 Month Momentum % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lattice Biologics's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Lattice Biologics's 12-1 Month Momentum % falls into.



Lattice Biologics  (OTCPK:LBLTF) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lattice Biologics  (OTCPK:LBLTF) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Lattice Biologics 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Lattice Biologics's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Lattice Biologics (Lattice Biologics) Business Description

Traded in Other Exchanges
N/A
Address
512 East Madison Avenue, Suite A1, Belgrade, MT, USA, 59714
Lattice Biologics Ltd is a biologic product manufacturing company. It manufactures and markets biologic products to domestic and international markets. The products of the company include ADM dermis, DBM Putty, Bone scaffold, and Others, of which key revenue is derived from Bone scaffold. The biologic products are used in various applications such as enhancing fusion in spine surgery, enhancing breast reconstruction post mastectomy for breast cancer patients, sports medicine applications, promotion of bone in foot and ankle surgery, promotion of skull healing following neurosurgery, and subchondral bone defect repair in knee and other joint surgeries. The company generates its revenue from operations principally carried in the United States of America.

Lattice Biologics (Lattice Biologics) Headlines

No Headlines